Bicara Therapeutics Inc.
BCAX
$24.28
$0.652.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 11.27% | 56.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.48% | 46.50% | |||
| Operating Income | 0.48% | -46.50% | |||
| Income Before Tax | 1.40% | -50.43% | |||
| Income Tax Expenses | 17.31% | -1.89% | |||
| Earnings from Continuing Operations | 1.38% | -50.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.38% | -50.35% | |||
| EBIT | 0.48% | -46.50% | |||
| EBITDA | 0.48% | -46.54% | |||
| EPS Basic | 11.85% | -36.55% | |||
| Normalized Basic EPS | 11.87% | -36.63% | |||
| EPS Diluted | 11.85% | -36.55% | |||
| Normalized Diluted EPS | 11.87% | -36.63% | |||
| Average Basic Shares Outstanding | 11.87% | 10.11% | |||
| Average Diluted Shares Outstanding | 11.87% | 10.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||